Pentostatin in steroid-refractory acute graft-versus-host disease
about
Secondary treatment of acute graft-versus-host disease: a critical reviewPentostatin in chronic lymphocytic leukemiaSafety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.Current and future approaches for control of graft-versus-host disease.Pathogenesis and management of graft-versus-host disease.Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studyThe pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.Management of acute graft-versus-host disease in children.Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.Acute graft versus host disease.Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsTocilizumab for steroid refractory acute graft-versus-host diseaseLymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.Tocilizumab for the treatment of steroid refractory graft-versus-host disease.Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials NetworkTreatment and management of graft-versus-host disease: improving response and survival.Acute graft-versus-host disease: are we close to bringing the bench to the bedside?Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.Emerging drugs for acute graft-versus-host disease.Mesenchymal stem cells targeting the GVHD.Acute graft-versus-host disease: new treatment strategies.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.State-of-the-art acute and chronic GVHD treatment.Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials NetworkSirolimus for treatment of steroid-refractory acute graft-versus-host disease.Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease.Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone MarrLow-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease.Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.New and emerging therapies for acute and chronic graft versus host disease.Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.
P2860
Q26823275-7E20F409-4861-4505-9BFD-F2B86CBC40B1Q28291531-BE87781D-E6ED-451D-AEE7-7579A68CC731Q33411063-16730F3F-9191-4EB6-9B55-52C0404631CFQ33642625-64974A42-17D8-4CCF-B78E-193650929B36Q34077479-66651D58-6F3A-495A-9B83-5B628E94C18CQ34666851-51252F0A-13DA-444B-941C-8D371E02A5C4Q34700443-C09CE070-0AA9-4F1A-927C-19AF3CF56019Q35023967-F9F88AD7-2D9F-4E5F-9E9B-12EC0B3A1EF4Q35583009-53615EB1-9DFA-4B8D-AAA2-A9C41554D138Q35760517-8646C55C-EB9B-4B01-B876-4CB0D7C663E1Q36059671-D4687C2F-C159-4DF9-846F-E06567DF85EAQ36380188-CD2479DE-5069-4BB5-87A7-C13B7CB9ADA9Q36422339-D03452CB-1BE2-481A-88DC-A19DEE5D1F87Q36841805-45D676F7-AC75-4F95-A231-4D3E50A79797Q36861714-06599430-A58C-4D82-8F4F-3A40A71DE80FQ36904078-3DC6C790-D7C0-48FC-A18E-0DCAE697C20BQ37026278-02CAA216-8DCC-4935-94CD-3A99076D3DC7Q37039069-F02A5860-1E7B-47EB-BD67-20C068EA752CQ37268948-22D5D99A-7B94-480A-826A-342EF83498C8Q37371836-436F5E55-CEFB-47EF-84DA-9052FDA83F70Q37402799-C1401268-B00A-4044-B4D6-D0184F4C53FCQ37468247-268CA0F9-3247-4CFB-8664-CFFC6485C0EEQ37515433-8E5F680F-F1BE-45DB-948C-78BB36E2933EQ37566315-3DF96E84-C039-46AA-81D9-777BDDA914D2Q37610714-400A94F3-AFA1-4263-9413-FB0BA7E79216Q37851519-6B0E0EAA-F074-4122-8AD2-9B091B58892CQ38416376-ACF1CC8D-6666-4866-A49F-709EFB765FD6Q41290373-23B538BC-5EB5-4612-81CD-E9CA4E7E0037Q42149848-3CBD8C9E-5252-4E90-AF19-38E1FC86FC33Q43228479-811078B2-ED42-4418-B85D-F98EF816A900Q43273885-2979B009-FD3B-434C-AB81-B79F32C7A5ECQ44005585-2384B629-F359-4236-98FF-C37512AB7FB1Q44847537-9A797F79-0310-40AA-83DD-6BD1A924B863Q46584471-6A475532-6385-4D18-B815-2CB3BB22BCF0Q46890990-14CB51E5-BFC3-43A4-AC29-0C1458C7E9BCQ48191465-D2BF71C6-C428-4BF1-A10F-393C0EF01ED3Q48281486-335D16D1-C473-4F2F-A585-54A11E5FAD5FQ48362201-5B35DB79-6106-4212-A822-F5F44D0ED671Q49238507-CF50EA49-5C9E-492F-8AF9-F17CB93247D1Q50069823-A6EE1628-A37C-48C4-A2D3-7E1BE3714D0D
P2860
Pentostatin in steroid-refractory acute graft-versus-host disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pentostatin in steroid-refractory acute graft-versus-host disease
@ast
Pentostatin in steroid-refractory acute graft-versus-host disease
@en
Pentostatin in steroid-refractory acute graft-versus-host disease
@nl
type
label
Pentostatin in steroid-refractory acute graft-versus-host disease
@ast
Pentostatin in steroid-refractory acute graft-versus-host disease
@en
Pentostatin in steroid-refractory acute graft-versus-host disease
@nl
prefLabel
Pentostatin in steroid-refractory acute graft-versus-host disease
@ast
Pentostatin in steroid-refractory acute graft-versus-host disease
@en
Pentostatin in steroid-refractory acute graft-versus-host disease
@nl
P2093
P356
P1476
Pentostatin in steroid-refractory acute graft-versus-host disease
@en
P2093
Adam Ogden
David A Jacobsohn
David M Lucas
Georgia B Vogelsang
Javier Bolaños-Meade
Jeffrey Margolis
M Guillaume Wientjes
Michael R Grever
Michele Phelps
Viki Anders
P304
P356
10.1200/JCO.2005.06.130
P407
P50
P577
2005-04-20T00:00:00Z